CytRx reports plans to price public offering of common stock, warrants

Proceeds finance clinical development and general corporate purposes

By Devika Patel

Knoxville, Tenn., July 26 - CytRx Corp. plans a public offering of common stock and warrants, according to a prospectus supplement filed Tuesday with the Securities and Exchange Commission. The deal has a greenshoe.

Cowen and Co. and Roth Capital Partners are the underwriters.

Proceeds will be used for clinical development and general corporate purposes.

Based in Los Angeles, CytRx develops human therapeutics.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.